2nd Ophthalmic Drug Development and Delivery Summit
- PMID: 17184164
- DOI: 10.1517/17425247.4.1.77
2nd Ophthalmic Drug Development and Delivery Summit
Abstract
The Second Annual Ophthalmic Drug Development and Delivery Summit was held on 19 - 20 September 2006 in San Diego, CA, US. The 2-day symposium, having a highly focused theme, was packed with cutting-edge science, insightful overviews and networking opportunities. With a total of 11 recognized specialists presenting reviews and recent results in the advancement of ocular drug development and delivery, the invited expert speaking faculty presented the latest preclinical and clinical developments in novel ophthalmic therapies and drug delivery technology. The talks included various case studies from primary investigators and pharmaceutical companies touching upon key topics: updates on current clinical trials, study design issues, sustained delivery to the eye, views of the vitreous space as a drug reservoir, new developments in dry and wet age-related macular degeneration and diabetic retinopathy, formulation for optimal drug delivery, differences and similarities in developing drugs for the eye compared with other targets, pharmacokinetics, novel ocular delivery methods and devices, delivery of proteins and peptides, focal drug delivery, non-invasive drug delivery to the eye, neuroprotection challenges, in vitro and in vivo models for glaucoma and angiogenesis for early efficacy estimation, and toxicology. Overall, the 2-day annual symposium continues to grow as an efficient platform for fostering discussion on a range of scientific topics and challenges and avenues for building collaborative partnerships in ophthalmic drug development.
Similar articles
-
Preclinical challenges for developing long acting intravitreal medicines.Eur J Pharm Biopharm. 2020 Aug;153:130-149. doi: 10.1016/j.ejpb.2020.05.005. Epub 2020 May 21. Eur J Pharm Biopharm. 2020. PMID: 32445965
-
Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications.Drugs Aging. 2007;24(7):581-602. doi: 10.2165/00002512-200724070-00006. Drugs Aging. 2007. PMID: 17658909 Review.
-
Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.Adv Drug Deliv Rev. 2005 Dec 13;57(14):2063-79. doi: 10.1016/j.addr.2005.08.006. Epub 2005 Nov 28. Adv Drug Deliv Rev. 2005. PMID: 16310884 Review.
-
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.Nat Rev Drug Discov. 2012 Jun 15;11(7):541-59. doi: 10.1038/nrd3745. Nat Rev Drug Discov. 2012. PMID: 22699774 Review.
-
Ocular angiogenesis: translating preclinical indications to successful clinical development.Expert Opin Ther Targets. 2004 Jun;8(3):255-8. doi: 10.1517/14728222.8.3.255. Expert Opin Ther Targets. 2004. PMID: 15161431
Cited by
-
Solution formulation development of a VEGF inhibitor for intravitreal injection.AAPS PharmSciTech. 2011 Mar;12(1):362-71. doi: 10.1208/s12249-011-9591-4. Epub 2011 Feb 11. AAPS PharmSciTech. 2011. PMID: 21312012 Free PMC article.
-
Effect of eye pigmentation on transscleral drug delivery.Invest Ophthalmol Vis Sci. 2008 Jan;49(1):333-41. doi: 10.1167/iovs.07-0214. Invest Ophthalmol Vis Sci. 2008. PMID: 18172110 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical